Cancer Vaccine Market Analysis, Size, Share & Growth Forecast 2026–2034

Moderna mRNA-4157 Personalised Neoantigen Vaccine Combined With Pembrolizumab Demonstrating Improved Relapse-Free Survival in Adjuvant Melanoma Is the First Phase II Signal That Personalised mRNA Cancer Vaccines Add Clinical Benefit Beyond Checkpoint Inhibition Alone.Moderna-Merck's 49% melanoma recurrence reduction has prompted BioNTech's accelerated MERIT and MELODIC personalised vaccine Phase 2 programmes, Gritstone bio's self-amplifying mRNA CORAL programme in colorectal cancer, and BioNTech's acquisition of Neon Therapeutics to consolidate neoantigen prediction expertise with mRNA manufacturing. The neoantigen discovery and manufacturing workflow achieving 45-day turnaround at scale requires parallel investment in tumour sequencing capacity, HLA-typing, machine learning neoantigen ranking, and modular mRNA synthesis that no company had commercially optimised before KEYNOTE-942 results validated the investment case. Extension of personalised cancer vaccine programmes into colorectal, NSCLC, bladder, and pancreatic cancer is advancing through KEYNOTE programme expansions, recognising that tumour mutational burden varies substantially across histologies and that high-TMB melanoma response may not translate uniformly into all tumour types.

Cancer Vaccine and Checkpoint Inhibitor Combination Rationale Based on Vaccine-Generated T Cells Released From Tumour Suppression by Checkpoint Blockade Is the Mechanistic Basis That Justifies the PD-1 Combination Across Therapeutic Cancer Vaccine Programmes.ISA Biologics's ISA101 and Inovio Pharmaceuticals's INO-3112 DNA vaccine targeting HPV E6 and E7 demonstrate proof-of-concept immune activation against HPV-derived antigens expressed in HPV-positive cervical and oropharyngeal tumours without expression in normal host tissue, providing the ideal therapeutic vaccine scenario where the target is both tumour-specific and foreign. Next-generation HPV therapeutic vaccines using mRNA platforms from BioNTech and Moderna encode HPV E6 and E7 as highly immunogenic antigens generating CD8 T-cell responses superior to DNA and viral vector predecessors, and the clinical success of mRNA-prophylactic vaccines provides manufacturing and regulatory confidence for the same platform in therapeutic applications. The clinical success of Merck's prophylactic Gardasil programme in virtually eliminating HPV-associated cervical cancer in vaccinated cohorts contextualises the therapeutic vaccine objective as achieving equivalent protection through immunity induction in already-infected patients.

HPV Prophylactic Vaccine ACIP Expansion to Age 27 to 45 Mid-Adult Vaccination Recognising That Gardasil 9 Prevents New Infections in Sexually Active Adults Has Extended the Cancer Prevention Benefit Beyond the Adolescent Vaccination Programme That the Prior Recommendation Targeted.Iovance Biotherapeutics's lifileucel Amtagvi demonstrated 31.5% objective response rate in heavily pre-treated melanoma patients after prior anti-PD-1 therapy, earning FDA accelerated approval in February 2024 as the first approved TIL therapy and establishing a third cellular immunotherapy category alongside CAR-T in haematological malignancy and dendritic cell therapy in prostate cancer. The TIL manufacturing process isolates autologous tumour-specific T cells from surgically resected tumour specimens, performs rapid expansion for approximately 22 days in IL-2, and cryopreserves a product containing billions of polyclonal T cells with diverse tumour-recognition capacity not achievable by antigen-directed CAR-T products. Iovance's GEN-2 manufacturing process reducing TIL expansion from 22 to 16 days and improving product yield consistency is critical for commercial scaling, and extension into cervical, NSCLC, and head and neck cancer is advancing based on the melanoma approval regulatory precedent.

For related market intelligence, see the Vaccine Market.